Present and future of lung cancer vaccines

Bibliography

• WOO EY, YEH H, CHU CS et al.: Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J. Immunol. (2002) 168:4272-4276.
   PubMed Web of Science ®Google Scholar
• DISIS ML, WEST HL, SCHIFFMAN K: Cancer vaccines for the treatment and prevention of non-small cell lung cancer. Clin. Lung Cancer (2000) 1(4):294-301.
   PubMedGoogle Scholar
• GROH V, WU J, YEE C, SPIES T: Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature (2002) 419(6908):734-738.
   PubMed Web of Science ®Google Scholar
• SOMASUNDARAM R, JACOB L, SWOBODA R et al.: Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-β. Cancer Res. (2002) 62:5267-5272.
   PubMed Web of Science ®Google Scholar
• SHEVACH EM: CD4+CD25+ suppressor T cells: more questions than answers. Nat. Rev. Immunol. (2002) 2(6):389-400.
   PubMed Web of Science ®Google Scholar
• WOO EY, CHU CS, GOLETZ TJ et al.: Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. (2001) 61(12):4766-4772.
   PubMed Web of Science ®Google Scholar
• ONIZUKA S, TAWARA I, SHIMIZU J, SAKAGUCHI S, FUJITA T, NAKAYAMA E: Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody. Cancer Res. (1999) 59(13):3128-3133.
   PubMed Web of Science ®Google Scholar
• SHIMIZU J, YAMAZI S, SAKAGUCHI S: Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. (1999) 163(10):5211-5218.
   PubMed Web of Science ®Google Scholar
• VIEWEG J, SU Z, DANNULL J: Enhancement of antitumor immunity following depletion of CD4+CD25+ regulatory T-cells. J. Clin. Oncol. (2004) 22(14S):164s (abstract 2506).
   Google Scholar
• THUN MJ, HENLEY J, BURNS D et al.: Lung cancer death rates in lifelong nonsmokers. J. Natl. Cancer Inst. (2006) 98(10):691-699.
   PubMed Web of Science ®Google Scholar
• MOUNTAIN CF: Revisions in the International System for staging lung cancer. Chest (1997) 111:1710-1717.
   PubMed Web of Science ®Google Scholar
• KRASANA MJ, REED CE, NUGENT WC et al.: Lung cancer staging and treatment in multidisciplinary trials: cancer and leukemia group B cooperative group approach. Ann. Thorac Surg. (1999) 68:201-207.
   PubMed Web of Science ®Google Scholar
• SCHILLER JH, HARRINGTON D, BELANI P et al.: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. (1999) 346(2):92-98.
   Google Scholar
• FOSELLA F, PEREIRA JR, VON PAWEL J et al.: Randomized, multinational, Phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J. Clin. Oncol. (2003) 21:3016-3024.
   PubMed Web of Science ®Google Scholar
• SCAGLIOTTI GV, DE MARINIS F, RINALDI M et al.: Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J. Clin. Oncol. (2002) 20:4285-4291.
   PubMed Web of Science ®Google Scholar
• SHEPHERD FA, RODRIGUES PJ, CIULEANU T et al.: Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. (2005) 353:123-132.
   PubMed Web of Science ®Google Scholar
• NON-SMALL CELL LUNG CANCER COOPERATIVE GROUP: Chemotherapy in non-small cell lung cancer: a meta analysis using updated data on individual patients from 52 randomized clinical trials. BMJ (1995) 311:899.
   PubMed Web of Science ®Google Scholar
• STEPHENS RJ, FAIRLAMB D, GOWER N et al.: The Big Lung Trial (BLT): determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC). Preliminary results in the supportive care setting. Proc. Am. Soc. Clin. Oncol. (2002) 21:291a (abstract 1161).
   Google Scholar
• LILENBAUM RC, HERNDON J, LIST M et al.: Single-agent versus combination chemotherapy in advanced non-small cell lung cancer (NSCLC): the cancer and leukemia group B (CALGB) 9730 study. J. Clin. Oncol. (2005) 23(1):190-196.
   PubMed Web of Science ®Google Scholar
• SEDERHOLM C: Gemcitabine versus gemcitabine/carboplatin in advanced non-small cell lung cancer: preliminary findings in a Phase III trial of the Swedish Lung Cancer Study Group. Semin. Oncol. (2002) 29(3 Suppl. 9):50-54.
   PubMedGoogle Scholar
• GEORGOULIAS V, PALLIS AG, KOUROUSIS et al.: Docetaxel versus docetaxel/cisplatin in patients with advanced non-small-cell lung cancer: preliminary analysis of a multicenter, randomized Phase III study. Clin. Lung Cancer (2003) 4(5):288-293.
   PubMedGoogle Scholar
• GEORGOULIAS V, PAPADAKIS E, ALEXOPOULOS A et al.: Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomized multicentre trial. Lancet (2001) 357:1478-1484.
   PubMed Web of Science ®Google Scholar
• KOSMIDIS P, MYLONAKIS N, NICOLAIDES C et al.: Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a Phase III randomized trial. J. Clin. Oncol. (2002) 20:3578-3585.
   PubMed Web of Science ®Google Scholar
• SMIT E, VAN MEERBEE, LIANES P et al.: Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non–small-cell lung cancer: a Phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group – EORTC 08975. J. Clin. Oncol. (2003) 21:3909-3917.
   PubMed Web of Science ®Google Scholar
• GRIDELLI C, GALLO C, SHEPHERD F et al.: Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non–small-cell lung cancer: a Phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. (2003) 21:3025-3034.
   PubMed Web of Science ®Google Scholar
• ALBEROLA B, CAMPS C, PROVENCIO M et al.: Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group Phase III randomized trial. J. Clin. Oncol. (2003) 21:3207-3213.
   PubMed Web of Science ®Google Scholar
• SCHILLER JH: Platin or no platin? That is the question. J. Clin. Oncol. (2003) 21:3009-3010.
   PubMed Web of Science ®Google Scholar
• SMITH IE, O’BRIEN ME, TALBOT DC et al.: Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J. Clin. Oncol. (2001) 19:1336-1343.
   PubMed Web of Science ®Google Scholar
• SOCINSKI MA, SCHELL MJ, PETERMAN A et al.: Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J. Clin. Oncol. (2002) 20:1335-1343.
   PubMed Web of Science ®Google Scholar
• ANDERSEN O, SORENSON S, BERGMAN B et al.: Duration of chemotherapy and survival in advanced non-small cell lung cancer (NSCLC). A multicenter, prospective randomized study. Lung Cancer (2003) 41:S28 (abstract O-87).
   Google Scholar
• BERGMAN B, SORENSON S, STEPHENS RJ et al.: Quality of life as related to duration of chemotherapy in advanced non-small cell lung cancer: a randomized study comprising 297 patients. Lung Cancer (2003) 41:S19 (abstract O-57).
   Google Scholar
• KRAZOWSKI M, WENCZL M, BRODOWICZ T et al.: Gemcitabine and cisplatin (GC) ± subsequent maintenance therapy with single-agent gemcitabine in advanced non-small cell lung cancer (NSCLC): preliminary results of a randomized trial of the Central European Cooperative Oncology Group (CECOG). Lung Cancer (2003) 41:S29 (abstract O-88).
   Google Scholar
• LIPSON SD, CHRETIEN PB, MAKUCH R, KENADY DE, COHEN MH: Thymosin immunotherapy in patients with small cell carcinoma of the lung: correlation of in vitro studies with clinical course. Cancer (1979) 43(3):863-870.
   PubMed Web of Science ®Google Scholar
• ISSELL BF, VALDIVIESO M, HERSH EM, RICHMAN S, GUTTERMAN JU, BODEY GP: Combination chemo-immunotherapy for extensive non-oat cell lung cancer. Cancer Treat. Rep. (1978) 62(7):1059-1063.
   PubMedGoogle Scholar
• EINHORN LH, BOND WH, HORNBACK N, JOE BT: Long-term results in combined-modality treatment of small cell carcinoma of the lung. Semin. Oncol. (1978) 5(3):309-313.
   PubMed Web of Science ®Google Scholar
• YASUMOTO K, MANABE H, YANAGAWA E et al.: Nonspecific adjuvant immunotherapy of lung cancer with cell wall skeleton of Mycobacterium bovis Bacillus Calmette–Guerin. Cancer Res. (1979) 39(8):3262-3267.
   PubMed Web of Science ®Google Scholar
• YAMAMURA Y, SAKATINI M, OGURA T, AZUMA I: Adjuvant immunotherapy of lung cancer with BCG cell wall skeleton (BCG-CWS). Cancer (1979) 43(4):1314-1319.
   PubMed Web of Science ®Google Scholar
• HADZIEV S, MANDULOVA P, KAVAKLIEVA-DIMITROVA J et al.: BCG immunotherapy of lung cancer in a district oncology dispensary. I. Study of 860 patients with histologic diagnosis. Neoplasma (1982) 29(1):93-110.
   PubMed Web of Science ®Google Scholar
• MAURER LH, PAJAK T, EATON W et al.: Combined modality therapy with radiotherapy, chemotherapy, and immunotherapy in limited small-cell carcinoma of the lung: a Phase III cancer and Leukemia Group B Study. J. Clin. Oncol. (1985) 3(7):969-976.
   PubMed Web of Science ®Google Scholar
• MATTHAY RA, MAHLER DA, BECK GJ et al.: Intratumoral Bacillus Calmette–Guerin immunotherapy prior to surgery for carcinoma of the lung: results of a prospective randomized trial. Cancer Res. (1986) 46(11):5963-5968.
   PubMed Web of Science ®Google Scholar
• GIACCONE G, DEBRUYNE C, FELIP E et al.: Phase III study of BEC2/BCG vaccination in limited disease small cell lung cancer (LD-SCLC) patients, following response to chemotherapy and thoracic irradiation (EORTC 08971, the SILVA study). ASCO Ann. Meet. Proc. (2004) 22(14S):7020.
   Google Scholar
• SCHILLER JH, MORGAN-IHRIG C, LEVITT ML: Concomitant administration of interleukin-2 plus tumor necrosis factor in advanced non-small cell lung cancer. Am. J. Clin. Oncol. (1995) 18(1):47-51.
   PubMed Web of Science ®Google Scholar
• JANSEN RL, SLINGERLAND R, GOEY SH, FRANKS CR, BOLHUIS RL, STOTER G: Interleukin-2 and interferon-α in the treatment of patients with advanced non-small-cell lung cancer. J. Immunother. (1992) 12(1):70-73.
   PubMed Web of Science ®Google Scholar
• LISSONI P, TISI E, BARNI S et al.: Biological and clinical results of a neuro-immunotherapy with interleukin-2 and the pineal hormone melatonin as a first line treatment in advanced non-small cell lung cancer. Br. J. Cancer (1982) 66(1):155-158.
   Web of Science ®Google Scholar
• HANIBUCHI M, YANO S, NISHIOKA Y, YANAGAWA H, KAWANO T, SONE S: Therapeutic efficacy of mouse-human chimeric anti-ganglioside GM2 monoclonal antibody against multiple organ micrometastases of human lung cancer in NK cell-depleted SCID mice. Int. J. Cancer (1998) 78(4):480-485.
   PubMed Web of Science ®Google Scholar
• LARA PN JR, LAPTALO L, LONGMATE J et al.: Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and Phase II trial. Clin. Lung Cancer (2004) 5(4):231-236.
   PubMedGoogle Scholar
• KERR C: Bevacizumab and chemotherapy improves survival in NSCLC. Lancet Oncol. (2005) 6(5):266.
   Google Scholar
• TYAGI P: Bevacizumab, when added to paclitaxel/carboplatin, prolongs survival in previously untreated patients with advanced non-small-cell lung cancer: preliminary results from the ECOG 4599 trial. Clin. Lung Cancer (2005) 6(5):276-278.
   PubMedGoogle Scholar
• BELANI CP, RAMALINGAM S: Bevacizumab extends survival for patients with non-squamous non-small-cell lung cancer. Clin. Lung Cancer (2005) 6(5):267-268.
   PubMedGoogle Scholar
• VUILLEZ JP, KRAEBER-BODERE F, MORO D et al.: Radio-immunotherapy of small cell lung carcinoma with the two-step method using a bispecific anti-carcinoembryonic antigen/anti-diethylenetriaminepentaacetic acid (DTPA) antibody and iodine-131 Di-DTPA hapten: results of a Phase I/II trial. Clin. Cancer Res. (1999) 5(10 Suppl.):3259s-3267s.
   PubMed Web of Science ®Google Scholar
• LIU B, PODACK ER, ALLISON JP, MALEK TR: Generation of primary tumor-specific CTL in vitro to immunogenic and poorly immunogenic mouse tumors. J. Immunol. (1996) 156:1117-1125.
   PubMed Web of Science ®Google Scholar
• GRANT SC, KRIS MG, HOUGHTON AN et al.: Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette–Guerin. Clin Cancer Res. (1999) 5:1319-1323.
   PubMed Web of Science ®Google Scholar
• GIACCONE G, DEBRUYNE C: Phase III study of BEC2/BCG vaccination in limited disease small cell lung cancer (LD-SCLC) patients, following response to chemotherapy and thoracic irradiation (EORTC 08971, the SILVA study). J. Clin. Oncol. (2004) 22(14S):622s (abstract 7020).
   Google Scholar
• SALGIA R, LYNCH T, SKARIN A et al.: Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony stimulating factor augments anti-tumor immunity in patients with metastatic non-small cell lung carcinoma. J. Clin. Oncol. (2004) 21(4):624-630.
   Web of Science ®Google Scholar
• NEMUNAITIS J, STERMAN D, JABLONS D et al.: Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J. Natl. Cancer Inst. (2004) 96(4):326-331.
   PubMed Web of Science ®Google Scholar
• NEMUNAITIS J: GVAX (GMCSF gene modified tumor vaccine) in advanced stage non small cell lung cancer. J. Control. Release (2003) 91(1-2):225-231.
   PubMed Web of Science ®Google Scholar
• SCHILLER J, NEMUNAITIS J, ROSS H et al.: A Phase II randomized study of GM-CSF gene-modified autologous tumor vaccine (CG8123) with and without low-dose cyclophosphamide in advanced stage non-small cell lung cancer (NSCLC). Lung Cancer (2005) 49(Suppl. 2):S91.
   Google Scholar
• PALMER M, PARKER J, MODI S et al.: Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small cell lung cancer. Clin. Lung Cancer (2001) 3(1):49-57.
   PubMedGoogle Scholar
• MURRAY N, BUTTS C, MAKSYMIUK A, MARSHALL E, GOSS G, SOULIERES D: L-BLP25 Non-Small Cell Lung Cancer Study Group. A liposomal MUC1 vaccine for treatment of non-small cell lung cancer (NSCLC); updated survival results from patients with stage IIIB disease. Proc. Am. Soc. Clin. Oncol. (2005) 23:7037.
   Google Scholar
• HIRSCHOWITZ EA, FOODY T, KRYSCIO R, DICKSON L, STURGILL J, YANNELLI J: Autologous dendritic cell vaccines for non-small-cell lung cancer. J. Clin. Oncol. (2004) 22(14):2808-2815.
   PubMed Web of Science ®Google Scholar
• YANNELLI JR, STURGILL J, FOODY T, HIRSCHOWITZ E: The large scale generation of dendritic cells for the immunization of patients with non-small cell lung cancer (NSCLC). Lung Cancer (2005) 47(3):337-350.
   PubMed Web of Science ®Google Scholar
• RAEZ LE, CASSILETH PA, SCHLESSELMAN J et al.: Allogeneic vaccination with a B7.1 (CD80) HLA-A gene modified adenocarcinoma cell line in patients with advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. (2004) 22(14):2800-2807.
   PubMed Web of Science ®Google Scholar
• HORIG H, LEE DS, CONKRIGHT W et al.: Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol. Immunother. (2000) 49(9):504-514.
   PubMed Web of Science ®Google Scholar
• ERTL HC: Technology evaluation: ALVAC-CEA/B7.1, Aventis Pasteur/Therion. Curr. Opin. Mol. Ther. (2002) 4:601-605.
   PubMed Web of Science ®Google Scholar
• OKA Y, TSUBOI A, TAGUCHI T et al.: Induction of WT1 (Wilm’s tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc. Natl. Acad. Sci. USA (2004) 101(38):13885-13890.
   PubMed Web of Science ®Google Scholar
• ATANACKOVIC D, ALTORKI NK, STOCKERT E et al.: Vaccine-induced CD4+ T cell response to MAGE-3 protein in lung cancer patients. J. Immunol. (2004) 172:3289-3296.
   PubMed Web of Science ®Google Scholar
• HEGE KM, CARBONE DP: Lung cancer vaccines and gene therapy. Lung Cancer (2003) 41:S103-S113.
   PubMed Web of Science ®Google Scholar
• VANSTEENKISTE J, ZIELINSKI M, DAHABRE J et al.: Multi-center, double-blind, randomized, placebo-controlled Phase II study to assess the efficacy of recombinant MAGE-A3 vaccine as adjuvant therapy in stage IB/II MAGE-A3-positive, completely resected, non-small cell lung cancer (NSCLC). ASCO Ann. Meet. Proc. (2006) 24(18S):7019.
   Google Scholar
• BRUNSVIG PF, GJERTSEN M, KVALHEIM G et al.: A Phase I/II study of telomerase peptide vaccination of patients with non-small cell lung cancer. J. Clin. Oncol. (2005) 23(16S):185s (abstract 2580).
   Google Scholar
• MORRIS JC, VAHANIAN N, JANIK JE et al.: Phase I study of an antitumor vaccination using α-(1,3) galactosyltransferase expressing allogeneic tumor cells in patients (Pts) with refractory or recurrent non-small cell lung cancer (NSCLC). J. Clin. Oncol. (2005) 23(16S):187s (abstract 2586).
   Google Scholar
• GONZALEZ G, CROMBET T, TORRES F et al.: Epidermal growth factor-based cancer vaccine for non-small cell lung cancer therapy. Ann. Oncol. (2003) 14(3):461-466.
   PubMed Web of Science ®Google Scholar
• SALAZAR LG, FIKES J, SOUTHWOOD S et al.: Immunization of cancer patients with Her-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles. Clin. Cancer Res. (2003) 9:5559-5565.
   PubMed Web of Science ®Google Scholar
• NEMUNAITIS J, DILLMAN RO, SCHWARZENBER P et al.: Phase II study of a TGF-β2 antisense gene modified allogeneic tumor cell vaccine (Lucanix) in advanced NSCLC. ASCO Ann. Meet. Proc. (2006) 24(18S):7018.
   Google Scholar
• YAMAZAKI K, NGUYEN T, PODACK ER: Cutting edge: tumor secreted heat shock-fusion protein elicits CD8 cells for rejection. J. Immunol. (1999) 163:5178-5182.
   PubMed Web of Science ®Google Scholar
• ANDERSON KM, SRIVASTAVA PK: Heat, heat shock, heat shock proteins and death: a central link in innate and adaptive immune responses. Immunol. Lett. (2000) 74(1):35-39.
   PubMed Web of Science ®Google Scholar
• KNUTSON KL: Technology evaluation: DCVax, Northwest Biotherapeutics. Curr. Opin. Mol. Ther. (2002) 4(4):403-407.
   PubMed Web of Science ®Google Scholar
• GABRILOVICH DI, MIRZA N, CHIAPPORI A et al.: Initial results of a Phase II trial of patients with extensive stage small cell lung cancer (SCLC) immunized with dendritic cells (DC) transduced with wild-type p53. J. Clin. Oncol. (2005) 23(16S):176s (abstract 2543).
   Google Scholar
• KRUG LM, RAGUPATHI G, HOOD C et al.: Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin. Clin. Cancer Res. (2004) 10:6094-6100.
   PubMed Web of Science ®Google Scholar
• CELLA M, SALLUSTO F, LANZAVECCHIA A: Origin, maturation and antigen presenting function of dentritic cells. Curr. Opin. Immunol. (1997) 9(1):10-16.
   PubMed Web of Science ®Google Scholar
• CELLA M, ENGERING A, PINET V, PIETERS J, LANZAVECHIA A: Inflammatory stimuli induce accumulation of MHC class II complexes on dentritic cells. Nature (1997) 388(6644):782-787.
   PubMed Web of Science ®Google Scholar
• LEE CT, WU LF, CIERNIK CH, NADAF-RAHROV, GABRILOVICH D, CARBONE DP: Genetic immunotherapy of established tumors with adenovirus-murine granulocyte-macrophage colony-stimulating factor. Hum. Gene Ther. (1997) 8:187-193.
   PubMed Web of Science ®Google Scholar
• NAGAI E, OGAWA T, KIELIAN A, IKUBO A, SUZUKI T: Irradiated tumor cells adenovirally engineered to secrete granulocyte/macrophage-colony-stimulating factor establish anittumor immunity and eliminate pre-existing tumorsin syngenic mice. Cancer Immunol. Immunother. (1998) 47:72-80.
   PubMed Web of Science ®Google Scholar
• DRANOFF G, JAFFEE E, LAZENBY A et al.: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA (1993) 90:3539-3543.
   PubMed Web of Science ®Google Scholar
• MACHIELS J, REILLY R, EMENS L et al.: Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res. (2001) 61:3689-3697.
   PubMed Web of Science ®Google Scholar
• JOHNSTON JV, MALACKO AR, MIZUNO MT et al.: B7-CD28 costimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes. J. Exp. Med. (1996) 183:791-800.
   PubMed Web of Science ®Google Scholar
• LIU B, PODACK ER, ALLISON JP, MALEK TR: Generation of primary tumorspecific CTL in vitro to immunogenic and poorly immunogenic mouse tumors. J. Immunol. (1999) 156:1117-1125.
   Google Scholar
• NABEL GJ, GORDON D, BISHOP DK et al.: Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc. Natl. Acad. Sci. USA (1996) 93:15388-15393.
   PubMed Web of Science ®Google Scholar
• YAMAZAKI K, SPRUILL G, RHODERICK J, SPIELMAN J, SAVARAJ N, PODACK ER: Small cell lung carcinomas express shared and private tumor antigens presented by HLA-A1 or HLA-A2. Cancer Res. (1999) 59:4642-4650.
   PubMed Web of Science ®Google Scholar
• VELDERS MP, SCHREIBER H, KAST WM: Active immunization against cancer cells: impediments and advances. Semin. Oncol. (1998) 25:697-706.
   PubMed Web of Science ®Google Scholar
• YAMADA A, KAWANO K, KOGA M et al.: Gene and peptide analyses of newly defined lung cancer antigens recognized by HLA-A2402-restricted tumor-specific cytotoxic T lymphocytes. Cancer Res. (2003) 63:2829-2835.
   PubMed Web of Science ®Google Scholar
• FONG L, ENGLEMAN EG: Dendritic cells in cancer immunotherapy. Ann. Rev. Immunol. (2000) 18:245-273.
   PubMed Web of Science ®Google Scholar
• BOON T, CEROTTINI JC, VAN DEN EYNDE B et al.: Tumor antigens recognized by T lymphocytes. Ann. Rev. Immunol. (1994) 12:337-365.
   PubMed Web of Science ®Google Scholar
• DRUG LM, GRANT SC, MILLER VA et al.: Strategies to erradícate minimal residual disease in small cell lung cancers: high dose chemotherapy with autologous bone marrow transplantation, matrix metalloproteinase inhibitors and BEC2 plus BCG vaccination. Semin. Oncol. (1999) 26:55-61.
   Google Scholar
• DING L, LALANI EN, REDDISH M et al.: Immunogenecity of synthetic peptides related to the corepeptide sequence encodedby the human MUC1 gene effect of immunization on the growth of murine mamary adenocarcinoma cells transfected with the human MUC1 gene. Cancer Immunol. Immunother. (1993) 36:9-17.
   PubMed Web of Science ®Google Scholar
• WROBLEWSKI JM, BIXBY DL, BOROWSKI C, YANNELLI JR: Characterization of human non-small cell lung cancer (NSCLC) cell lines for expression of MHC, co-stimulatory molecules and tumor-associated antigens. Lung Cancer (2001) 33(2-3):181-194.
   PubMed Web of Science ®Google Scholar